Innovative agents for actinic keratosis and nanocarriers enhancing skin penetration

Skin Pharmacology and Physiology

Volumn 23, Issue 1, 2010, Pages 6-14

  Schafer Korting M ^a   Holtje M ^b   Korting, H C ^c   Holtje H D ^b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Core multishell nanotransporters; DNA polymerase ; Nucleosides; Polymerase inhibitors; Skin cancer; Solid lipid nanoparticles

Indexed keywords

APHIDICOLIN; CYTARABINE; DNA DIRECTED DNA POLYMERASE ALPHA; FLUOROURACIL; GEMCITABINE; GUANOSINE; NANOCARRIER; NUCLEOTIDE TRANSPORTER; POL PROTEIN; PRODRUG; PROTEIN MRP 4; PROTEIN MRP 5; THYMIDINE; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; CANCER THERAPY; CELL PROLIFERATION; CELL VIABILITY; CYTOTOXICITY; DNA SYNTHESIS; DRUG TOLERABILITY; HUMAN; IC 50; IN VITRO STUDY; KERATINOCYTE; MOLECULAR DYNAMICS; MOLECULAR MODEL; MOLECULAR WEIGHT; NONHUMAN; NUCLEOTIDE METABOLISM; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SKIN CARCINOMA; SKIN PENETRATION; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET RADIATION;

ADMINISTRATION, CUTANEOUS; AGING; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; KERATOSIS, ACTINIC; MODELS, MOLECULAR; NANOPARTICLES; SKIN ABSORPTION; SKIN NEOPLASMS;

EID: 76749167973     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000257258     Document Type: Review

References (49)

1. Queille S, Luron L, Spatz A, Avil MF, Ribrag V, Duvillard P, Hiesse C, Sarasin A, Armand JP, Daya-Grosjean L: Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UVspecific tandem CC to TT mutations of the p53 gene. Carcinogenesis 2007; 28: 724-731.
2. Madkan VK, Cook-Norris RH, Steadman MC, Arora A, Mendoza N, Tyring SK: The oncogenic potential of human papillomaviruses: a review on the role of host genetics and environmental cofactors. Br J Dermatol 2007; 57: 228-241.
3. Dianzani C, Pierangeli A, Chiricozzi A, Avola A, Degener AM: Cutaneous human papillomaviruses as recurrence factor in actinic keratoses. Int J Immunopathol Pharmacol 2008; 21: 145-153.
4. Michel A, Kopp-Schneider A, Zentgraf H, Gruber AD, de Villers EM: E6/E7 expression of human papillomavirus type 20 (HPV-20) and HPV-27 influences proliferation and differentiation of the skin in UV-irradiated SKH-hr1 transgenic mice. J Virol 2006; 80: 1153-1164.
5. Jorizzo J: Topical treatment of actinic keratosis with fluorouracil: is irritation associated with efficacy? J Drugs Dermatol 2004; 3: 21-26.
6. Rhodes LE, de Rie M, Enstrom Y, Groves R, Morken T, Goulden V, Wong GA, Grob JJ, Varma S, Wolf P: Photodynamic therapy using topical methyl aminolevulinate vs. surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 2004; 140: 17-23.
7. Pariser D, Loss R, Jarratt M, Abromovits W, Spencer J, Geronemus R, Bailin P, Bruce S: Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2008; 59: 569-576 .
8. Wolf JE Jr, Taylor JR, Tschen E, Kang S: Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40: 709-713.
9. Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y: Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002; 146: 94-100.
10. Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, Lee JH, Fox TL: Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50: 714-721.
11. O'Dwyer PJ, Moyer JD, Suffness M, Harrison SD Jr, Cysyk R, Hamilton TC, Plowman J: Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. Cancer Res 1994; 54: 724-729.
12. Miura S, Izuta SI: DNA polymerases as targets of anticancer nucleosides. Curr Drug Targets 2004; 5: 191-195.
13. Maeda N, Kokai Y, Ohtani S, Sahara H, Kuriyama I, Kamisuki S, Takahashi S, Sakaguchi K, Sugawara F, Yoshida H, Sato N, Mizushina Y: Anti-tumor effects of dehydroaltenusin, a specific inhibitor of mammalian DNA polymerase alpha. Biochem Biophys Res Commun 2007; 352: 390-396.
14. Kuriyama I, Musumi K, Yonezawa Y, Takemura M, Maeda N, Iijima H, Hada T, Yoshida H, Mizushina Y: Inhibitory effects of glycolipids fraction from spinach on mammalian DNA polymerase activity and human cancer cell proliferation. J Nutr Biochem 2005; 16: 594-601. (Pubitemid 41338371)
15. Maeda N, Yoshida H, Sato N, Mizushina Y, Kokai Y, Ohtani S, Sahara H, Hada T, Ishimaru C, Kuriyama I, Yonezawa Y, Iijima H: Anti-tumor effects of the glycolipids fraction from spinach which inhibited DNA polymerase activity. Nutr Cancer 2007; 57: 216-223.
16. Matsubara K, Saito A, Tanaka A, Nakajima N, Akagi R, Mori M, Mizushina Y: Catechin conjugated with fatty acid inhibits DNA polymerase and angiogenesis. DNA C ell Biol 2006; 25: 95-103.
17. Matsubara K, Saito A, Tanaka A, Nakajima N, Akagi R, Mori M, Mizushina Y: Epicatechin conjugated with fatty acid is a potent inhibitor of DNA polymerase and angiogenesis. Life Sci 2007; 80: 1578-1585.
18. Alba M: Replicative DNA polymerases. Genome Biol 2001; 2:REVIEWS3002.
19. Steitz TA: DNA polymerases: structural diversity and common mechanisms. J Biol Chem 1999; 274: 17395-17398.
20. Richartz A, Holtje M, Brandt B, Schafer-Korting M, Holtje H-D: Targeting human polymerase for the inhibition of keratinocyte proliferation. 1. Homology model, active site architecture and ligand binding. J Enzyme Inhib Med Chem 2008; 23: 94-100.
21. Holtje M, Richartz A, Zdrazil B, Schwanke A, Dugovic B, Murruzzu C, Reissig HU, Korting HC, Kleuser B, Holtje HD, Schafer-Korting M: Human polymerase inhibitors for skin tumors. 2. Modelling, synthesis and influence on normal and transformed keratinocytes of new thymidine and purine derivatives. J Enzyme Inhib Med Chem, in press.
22. Keller DJ, Brozik JA: Framework model DNA polymerases. Biochemistry 2005; 44: 6877-6888.
23. Shi R, Azzi A, Gilbert C, Boivin G, Lin SX: Three-dimensional modelling of cytomegalovirus DNA polymerase and preliminary analysis of drug resistance. Proteins 2006; 64: 301-307.
24. Ren J, Stammers DK : Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reserve transcriptase. Virus Res 2008; 134: 157-170.
25. Spallarossa A, Cesarini S, Ranise A, Ponassi M, Unge T, Bolognesi M: Crystal structures of HIV-1 reverse transcriptase complexes with thiocarbamate non-nucleoside inhibitors. Biochem Biophys Res Commun 2008; 365: 764-770.
26. Ren J, Chamberlain PP, Stamp A, Short SA, Weaver KL, Romines KR, Hazen R, Freeman A, Ferris RG, Andrews CW, Boone L, Chan JH, Stammers DK: Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors. J Med Chem 2008; 51: 5000-5008.
27. Gysler A, Lange K, Korting HC, Schafer-Korting M: Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts. Pharm Res 1997; 14: 793-797.
28. Fedorocko P, Hoferova Z, Hofer M, Brezani P: Administration of liposomal muramyl tripeptide phosphatidylethanolamine (MTPPE) and diclofenac in the combination attenuates their anti-tumor activities. Neoplasma 2003; 50: 176-184.
29. Haberland A, Schreiber S, Santos Maia C, Rubbelke MK, Schaller M, Korting HC, Kleuser B, Schafer-Korting M: The impact of skin viability on drug metabolism and permeation-BSA toxicity on primary keratinocytes. Toxicol In Vitro 2006; 20: 347-354.
30. Baron JM, Holler D, Schiffer R, Frankenberg S, Neis M, Merk HF, Jugert FK: Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. J Invest Dermatol 2001; 116: 541-548.
31. Schiffer R, Neis M, Holler D, Rodriguez F, Geier A, Gartung C, Lammert F, Dreuw A, Zwadlo-Klarwasser G, Merk H, Jugert F, Baran JM: Active influx transport is mediated by members of the organic transporting polypeptide family in human epidermal keratinocytes. J Invest Dermatol 2003; 120: 285-291.
32. Korting HC, Schafer-Korting M: Carriers in the topical treatment of skin disease; in Schafer-Korting M (ed): Handbook of Experimental Pharmacology/Drug Delivery. Heidelberg, Springer, in press.
33. Muller RH, Petersen RD, Hommoss A, Pardeike J: Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 2007; 59: 522-530.
34. Santos Maia C, Mehnert W, Schaller M, Korting HC, Gysler A, Haberland A, Schafer-Korting M: Drug targeting by solid lipid nanoparticles for dermal use. J Drug Target 2002; 10: 489-495.
35. Lombardi Borgia S, Regehly M, Sivaramakrishnan R, Mehnert W, Korting HC, Danker K, Roder B, Kramer KD, Schafer-Korting M: Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J Control Release 2005; 110: 151-163.
36. Štecova J, Mehnert W, Blaschke T, Kleuser B, Sivaramakrishnan R, Zouboulis CC, Seltmann H, Korting HC, Kramer KD, Schafer-Korting M: Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake. Pharm Res 2007; 25: 991-1000.
37. Kuchler S, Radowski MR, Blaschke T, Dathe M, Plendl J, Haag R, Schafer-Korting M, Kramer KD: Nanoparticles for skin penetration enhancement-A comparison of a dendritic core-multishell-nanotransporter and solid lipid nanoparticles. Eur J Pharm Biopharm 2009; 71: 243-250.
38. Kuchler S, Abdel-Mottaleb M, Lamprecht A, Radowski MR, Haag R, Schafer-Korting M: Influence of nanocarrier type and size on skin delivery of hydrophilic agents. Int J Pharm 2009; 377: 169-172.
39. Haag R, Kratz F: Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl 2006; 45: 1198-1215.
40. Quadir MA, Radowski MR, Kratz F, Licha K, Hauff P, Haag R: Dentritic multishell architectures for drug and dye transport. J Control Release 2008; 132: 289-294.
41. Xu S, Luo Y, Graeser R, Warnecke A, Kratz F, Hauff P, Licha K, Haag R: Development of pH-responsive core-shell for delivery of therapeutic and diagnostic agents. Bioorg Med Chem Lett 2009; 19: 1030-1034.
42. Stasko NA, Johnson CB, Schoenfisch MH, Johnson TA, Holmuhamedov EL: Cytotoxicity of polypropylenimine dendrimer conjugates on cultured endothelial cell. Biomacromolecules 2007; 8: 3853-3859.
43. Hong S, Bielinska AU, Mecke A, Keszler B, Beals JL, Shi X, Balogh L, Orr BG, Baker JR, Banaszak Holl MM: Interaction of poly-(amidoamine) dendrimers with supported lipid bilayers and cells: hole information and the relation to transport. Bioconjug Chem 2004; 15: 774-782.
44. Moghimi SM, Szebeni J: Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003; 42: 463-478.
45. Scholer N, Olbrich C, Tabatt K, Muller RH, Hahn H, Liesenfeld O: Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages. Int J Pharm 2001; 221: 57-67.
46. Weyenberg W, Filev P, Van den Plas D, Vandervoort K, De Smet P, Sollie A, Ludwig A: Cytotoxicity of submicron emulsions and solid lipid nanoparticles for dermal application. Int J Pharm 2007; 337: 291-298.
47. Muller RH, Ruhl D, Runge S, Schulze-Forster K, Mehnert W: Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res 1997; 14: 458-462. (Pubitemid 27205004)
48. Scholer N, Hahn H, Muller RH, Liesenfeld O: Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int J Pharm 2002; 231: 167-176.
49. Wolf N, Kuchler S, Radowski MR, Blaschke T, Kramer KD, Weindl G, Kleuser B, Haag R, Schafer-Korting M: Influences of opioids and nanoparticles on in vitro wound healing models. Eur J Pharm Biopharm 2009; 73: 34-42.